Alten, Rieke http://orcid.org/0000-0002-3395-4412
Tony, Hans-Peter
Bannert, Bettina
Nüßlein, Hubert
Rauch, Christiane
Connolly, Sean E.
Chartier, Melanie
Lozenski, Karissa
Hackl, Roland
Forster, Adrian
Peichl, Peter
Funding for this research was provided by:
Bristol-Myers Squibb
Article History
Received: 27 February 2023
Revised: 17 May 2023
Accepted: 25 May 2023
First Online: 14 June 2023
Compliance with ethical standards
:
: The study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments, the International Conference on Harmonization Good Clinical Practice Guidelines, and the International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Epidemiology Practices. The laws and regulatory requirements of all countries participating in this study were adhered to. The study protocol and patient enrollment materials were approved according to local law in each participating country prior to initiation of the study.
: All participants signed an informed consent form prior to their participation in the study and agreed to have their data published for research purposes, given that the data provided were first anonymized.
: RA has received consulting fees from AbbVie, Bristol Myers Squibb, Celltrion, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and Roche; and has received grant/research support from Bristol Myers Squibb, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and Roche. BB, PP, AF, and HN declare no competing interests. CR (at time of analysis), MC, SEC, RH, and KL are employees of and shareholders in Bristol Myers Squibb. H-PT has received consulting fees from AbbVie, Bristol Myers Squibb, Chugai, Galapagos, Gilead, Janssen, Lilly, Novartis, and Roche.